Medicaments; consisting of mixed or unmixed products n.e.c. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale
Gene therapy drug Neovasculgen
Neovasculgen is a gene therapy drug for treatment of PAD – Peripheral Arterial Disease. The drug successfully passed all clinical trials in Russia and has proven to be 3-5 times more effective than any other treatment. To date more than 3000 patients treated and no SAEs observed. Clinical trials results are published in 3 US peer-reviewed journals.